Coadministration of VIRACEPT is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in Table 3 [also see Drug Interactions (7), Table 6].
| Drug Class | Drugs Within Class That Are Contraindicated With VIRACEPT | Clinical Comment |
|---|---|---|
| ||
Alpha 1-adrenoreceptor antagonist | Alfuzosin | Potentially increased alfuzosin concentrations can result in hypotension. |
Antiarrhythmics | Amiodarone, quinidine | Potential for serious and/or life-threatening cardiac arrhythmia. |
Antimycobacterial Agents | Rifampin | Plasma concentrations of nelfinavir can be reduced by concomitant use of rifampin. This may lead to loss of therapeutic effect and possible development of resistance to VIRACEPT or other coadministered antiretroviral agents. |
Antipsychotics | Lurasidone
| Potential for serious and/or life-threatening reactions. |
Ergot Derivatives | Dihydroergotamine, ergotamine, methylergonovine | Potential for serious and/or life threatening reactions such as ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. |
GI Motility Agent | Cisapride | Potential for serious and/or life threatening reactions such as cardiac arrhythmias. |
Herbal products | St. John's wort (Hypericum perforatum) | Plasma concentrations of nelfinavir can be reduced by concomitant use of the herbal preparation St. John's wort. This may lead to loss of therapeutic effect and possible development of resistance to VIRACEPT or other coadministered antiretroviral agents. |
HMG-CoA Reductase Inhibitors | Lovastatin, Simvastatin | Potential for serious reactions such as myopathy including rhabdomyolysis. |
PDE5 Inhibitors | Sildenafil (Revatio) [for treatment of pulmonary arterial hypertension]* | A safe and effective dose has not been established when used with nelfinavir. There is increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, prolonged erection, and syncope). |
Sedative/Hypnotics | Triazolam, oral midazolam | Potential for serious and/or life threatening reactions such as prolonged or increased sedation or respiratory depression. |
Coadministration of VIRACEPT is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in Table 3 [also see Drug Interactions (7), Table 6].
| Drug Class | Drugs Within Class That Are Contraindicated With VIRACEPT | Clinical Comment |
|---|---|---|
| ||
Alpha 1-adrenoreceptor antagonist | Alfuzosin | Potentially increased alfuzosin concentrations can result in hypotension. |
Antiarrhythmics | Amiodarone, quinidine | Potential for serious and/or life-threatening cardiac arrhythmia. |
Antimycobacterial Agents | Rifampin | Plasma concentrations of nelfinavir can be reduced by concomitant use of rifampin. This may lead to loss of therapeutic effect and possible development of resistance to VIRACEPT or other coadministered antiretroviral agents. |
Antipsychotics | Lurasidone
| Potential for serious and/or life-threatening reactions. |
Ergot Derivatives | Dihydroergotamine, ergotamine, methylergonovine | Potential for serious and/or life threatening reactions such as ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. |
GI Motility Agent | Cisapride | Potential for serious and/or life threatening reactions such as cardiac arrhythmias. |
Herbal products | St. John's wort (Hypericum perforatum) | Plasma concentrations of nelfinavir can be reduced by concomitant use of the herbal preparation St. John's wort. This may lead to loss of therapeutic effect and possible development of resistance to VIRACEPT or other coadministered antiretroviral agents. |
HMG-CoA Reductase Inhibitors | Lovastatin, Simvastatin | Potential for serious reactions such as myopathy including rhabdomyolysis. |
PDE5 Inhibitors | Sildenafil (Revatio) [for treatment of pulmonary arterial hypertension]* | A safe and effective dose has not been established when used with nelfinavir. There is increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, prolonged erection, and syncope). |
Sedative/Hypnotics | Triazolam, oral midazolam | Potential for serious and/or life threatening reactions such as prolonged or increased sedation or respiratory depression. |
{{section_name_patient}}
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.